Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

AAB Badawy - Bioscience Reports, 2020 - portlandpress.com
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …
被引用次数：46 相关文章

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

AAB Badawy - Bioscience reports, 2020 - pubmed.ncbi.nlm.nih.gov
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.

AA Badawy - Bioscience Reports, 2020 - europepmc.org
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide?

A Badawy - Authorea Preprints, 2020 - authorea.com
Background and purpose: COVID-19 induces a proinflammatory environment that is
stronger in cases requiring intensive care. Overexpression of the aryl hydrocarbon receptor …
[HTML] nih.gov

[HTML][HTML] Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

AAB Badawy - Bioscience Reports, 2020 - ncbi.nlm.nih.gov
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide?

A Badawy - Authorea Preprints, 2020 - advance.sagepub.com
COVID-19 patients in China exhibit a proinflammatory environment that is stronger in severe
cases requiring intensive care. The immunity modulators, the aryl hydrocarbon receptor …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide?

A Badawy - Authorea Preprints, 2020 - essopenarchive.org
COVID-19 patients in China exhibit a proinflammatory environment that is stronger in severe
cases requiring intensive care. The immunity modulators, the aryl hydrocarbon receptor …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.

AAB Badawy - Bioscience Reports, 2020 - search.ebscohost.com
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

ABB Abdulla - Bioscience Reports, 2020 - elibrary.ru
COVID-19 induces a proinflammatory environment that is stronger in patients requiring
intensive care. The cytokine components of this environment may determine efficacy or …

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide?

A Badawy - Authorea Preprints, 2020 - techrxiv.org
COVID-19 patients in China exhibit a proinflammatory environment that is stronger in severe
cases requiring intensive care. The immunity modulators, the aryl hydrocarbon receptor …